$PEN News
Last published 1w ago
- 1w agoPENPenumbra Inc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPENBSXPenumbra, Inc. Reports Third Quarter 2026 Financial ResultsPR NewswireALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
- 3w agoPENPenumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)PR NewswireBOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effectiveALAMEDA, Calif., Oct.
- 1mo agoPENNew STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary EmbolismPR NewswirePenumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to...
- 3mo agoPENBSXPenumbra, Inc. Reports Second Quarter 2026 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026....
- 3mo agoPENTHUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke CarePR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE)...
- 4mo agoPENFirst Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic StrokePR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world...
- 4mo agoPENPenumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLTPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the ...
- 5mo agoPENPenumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to StrokePR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for ...
- 6mo agoPENBSXPenumbra, Inc. Reports First Quarter 2026 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026....
- 7mo agoPENNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism PatientsPR NewswirePenumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute...
- 8mo agoPENPenumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended...
- 9mo agoBSXPENBoston Scientific announces results for fourth quarter and full year 2025PR NewswireBoston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported ...
- 10mo agoBSXPENBoston Scientific announces agreement to acquire Penumbra, Inc.PR NewswireBoston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement...
- 10mo agoPENPenumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the...
- 10mo agoPENPenumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on...
- 11mo agoPENPenumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on ...
- 1y agoPENPenumbra, Inc. Reports Third Quarter 2025 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025....
- 1y agoPENLatest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary EmbolismPR NewswirePenumbra, Inc. (NYSE: PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use...
- 1y agoPENLandmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary EmbolismPR NewswirePenumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical...
- 1y agoPENPenumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025PR NewswirePenumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 ...
- 1y agoPENPenumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoPENNew Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk ProfilePR NewswireThe American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:...
- 1y agoPENPenumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoPENPenumbra, Inc. Names Shruthi Narayan as Company PresidentPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company,...
- 1y agoPENPenumbra, Inc. to Present at Upcoming Investor ConferencesPR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and...
- 1y agoPENPenumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on ...
- 1y agoPENPenumbra, Inc. (PEN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPENPenumbra, Inc. Reports Second Quarter 2025 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025....
- 1y agoPENPenumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025PR NewswirePenumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market...
- 1y agoPENPenumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled TrialPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The...
- 1y agoPENPenumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular EmbolizationPR NewswirePenumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest...
- 1y agoPENPenumbra, Inc. to Present at Upcoming Investor ConferencesPR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and...
- 1y agoPENPenumbra, Inc. to Present at the BofA Securities 2025 Health Care ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on...
- 1y agoPENPenumbra, Inc. Reports First Quarter 2025 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025....
- 1y agoPENPenumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025PR NewswirePenumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market...
- 1y agoPENSeven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource BenefitsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data...
- 1y agoPENPenumbra, Inc. Announces Don Kassing will Retire from Board of DirectorsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has...
- 1y agoPENRapidPulse, Inc. vs Penumbra, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoPENPenumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended...
- 1y agoPENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025PR NewswirePenumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 ...
- 1y agoPENPenumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on...
- 1y agoPENPenumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare ConferencePR NewswirePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on ...
- 2y agoPENNew Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment OptionsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary...
- 2y agoPENPenumbra, Inc. (PEN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPENPenumbra, Inc. Reports Third Quarter 2024 Financial ResultsPR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024....
- 2y agoPENPenumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic StrokePR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for...
- 2y agoPENGet Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous ThromboembolismPR NewswireThe International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), The PERT Consortium™ ...
- 2y agoPENPenumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024PR NewswirePenumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market...
- 2y agoPENPenumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in EuropePR NewswirePenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted...